Business

CCI Approves Torrent Pharma’s Rs 19,500 Crore Acquisition of JB Chemicals, Paving Way for Major Industry Consolidation

The acquisition ranks as the second-largest pharma deal in Indian history, following Sun Pharma’s acquisition of Ranbaxy Laboratories in 2015.

• By Newsdesk
• New Delhi
• Oct 22, 2025

Business

India’s Competition Commission (CCI) has granted approval to Torrent Pharmaceuticals Ltd’s proposal to acquire J.B. Chemicals & Pharmaceuticals Ltd, marking one of the largest mergers in India’s pharmaceutical sector. The clearance comes with certain conditions tied to voluntary modifications proposed by both companies to address competition-related concerns.

The ₹19,500 crore transaction, first announced in June this year, is set to significantly reshape the dynamics of the Indian pharma market. Under the terms of the deal, Torrent will acquire a 46.39% stake in J.B. Chemicals from its promoter group for approximately ₹11,917 crore, along with an additional 2.8% from certain employees for ₹719 crore. Following this, Torrent will launch an open offer to purchase up to 26% of the remaining shares from public shareholders, valued at around ₹6,843 crore.

Once the transaction is complete, Torrent Pharmaceuticals will merge J.B. Chemicals into its operations, positioning itself as India’s second-largest pharmaceutical company by market value. The acquisition ranks as the second-largest pharma deal in Indian history, following Sun Pharma’s acquisition of Ranbaxy Laboratories in 2015.

The merger brings together Torrent’s strong domestic formulations portfolio and J.B. Chemicals’ diverse range of finished dosages, APIs, and contract manufacturing capabilities. Industry experts expect the combined entity to benefit from greater operational scale, portfolio diversification, and a stronger global presence.

The deal now moves into the next phase, involving shareholder approvals, open-offer acceptance, and integration of business operations. Once completed, the acquisition is expected to accelerate consolidation within India’s pharma landscape and strengthen Torrent’s position as a major force in the industry’s next growth chapter.